Business Wire

ICCPP-GROUP

9.5.2023 13:08:32 CEST | Business Wire | Press release

Share
ICCPP ODM+ Will Bring the Unheard-of Double Eco-friendly Concept "Cyclo" Vape Solutions To The Vaper Expo UK 2023 Birmingham

With the global prevalence of disposable e-cigarettes, there are growing concerns about the environmental problems caused. As one of key influencers of electronic atomization technology companies, as well as the parent company of VOOPOO, ICCPP Group takes these problems seriously and its ODM+ business has creatively developed world’s 1st new dual environmentally-friendly disposable vape solutions, named "Cyclo" series, which combines the concept of detachable and biodegradable, ahead of the industry in advance to achieve user portability and recyclability, will be grandly unveiled at the Vaper Expo UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005592/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The "Cyclo" eco-friendly vape solutions of ICCPP ODM+ (Photo: Business Wire)

Patented PLA Material: The Key to Make Stable Biodegradability Reality The "Cyclo" series are made with our exclusive and patented PLA material, a biodegradable material that is made from starch raw materials proposed from corn, a renewable plant resources, and which can be degraded into carbon dioxide and water in 3-6 months after being recycled and landfilled in the soil, making it a more environmentally friendly material.

In addition, ICCPP has gone through thousands of trials and tests and created a unique internal structure and process to further enhance the stability of unique PLA material, making it maintain its initial strength after thousands of drop and impact tests, to greatly improve the stability and safety of PLA e-cigarette sticks, without destroying the original biodegradable advantages of the material.

Leadless and Modular Design: Making Detachability A Reality

ICCPP’s commitment to environmental sustainability goes much further than just material selection.

We have implemented a wide range of environmentally-friendly design features, including no-soldering lead-free design and pre-automated modular assembly. These design features mean that "Cyclo" vape solutions can be easily disassembled for recycling or disposal, minimizing the environmental impact of manufacturing and using processes.

Multiple Options for Atomization Coils: The Addition of Environmental Concepts

ICCPP’s commitment to environmental sustainability does not end with the product itself. We have also advanced atomization coil technology into "Cyclo" series, resulting in a longer lifespan, less material waste, and a more stable and pure taste for vapers.

The atomization coil technology in the "Cyclo" vape solutions includes the mesh coil technology and the Gene Tree ceramic coil technology. On one hand, our mesh coil technology combines different resistivity application scenarios with a unique multi-layer distribution structure to precisely control the power at a single point and precisely calculate the heat field coverage at a single point to so that the heat is evenly distributed, resulting in a stable, perfect and pure taste.

On the other hand, the Gene Tree ceramic coil technology uses the exclusive powder-free environmental-friendly technology process, nano-microcrystalline ceramic material fired at 3000°, and a multi-layer A+ grade oil guide and oil lock aperture structure to provide more stable and uniform heating. This unique combination of technologies ensures that "Cyclo" e-cigarettes solutions provide customers with more puffs, purer tastes, greater flavor consistency and a superior vaping experience, as well as less environmental concerns .

The Origin of "Cyclo": The Commitment of ICCPP to the Environment and Society

In view of these, we name the electronic cigarettes solutions "Cyclo", representing our dedication to creating a closed-loop, circular product cycle that is both environmentally-friendly and sustainable. Also,the slogan of “Cyclo” is “Cycle of all things", and it reflects our dedications and determination to promoting environmental sustainability in all areas of our business.

In conclusion, the "Cyclo" series of e-cigarettes are the perfect choice for those who want an environmentally-friendly and sustainable vaping experience. With biodegradable materials, recyclable design features, cutting-edge atomization coil technology, as well as our commitment to environmental responsibility, we invite you to join us in the journey towards a more sustainable future.

Of course, apart from “Cyclo” eco-friendly products, ICCPP ODM+ brings dozens of vapes including refillable pods and disposable pods for UK e-cigarette enthusiasts and industry experts that meet local market flavor and puff preferences and also obey local regulations. Welcome to E10 booth at NEC of Birmingham and we look forward to seeing you on May 12th-14th 2023.

1)About ICCPP ODM+:

ICCPP ODM+ is an innovative ODM strategic cooperation model created by ICCPP Group in 2022, which puts forward the business proposition of “branding first, product integrating technology and marketing”.

Through all-round innovations and breakthroughs in technology+, product+, flavor+, quality+, compliance+ and marketing+, ICCPP ODM+ provides more premium vape solutions and services for customers' brands, so as to bring a healthier and happier electronic atomization life to global consumers and to achieve long-term development of both customers' brands and ICCPP ODM.

2)About ICCPP Group:

ICCPP Group, the parent company of VOOPOO, is a comprehensive electronic atomization ecological group with the whole industrial chain layout. It is rapidly developing with a new business model of matrix, internationalization and platform, integrating technology R&D, product design, intelligent manufacturing, brand operation and supply chain management.

With 9 years of full industry chain layout and global localization, ICCPP's electronic atomization products and solutions have been applied in more than 70 countries worldwide, covering 100,000 offline outlets and more than 36 million consumers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005592/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye